Now, Bioprocessing 4.0 is accepted by the biotechnology community as a responsive, self-correcting, complex system, and a radical break from the past.
Chris Mayhew, director of the Stem Cell Facility at Cincinnati Children’s Hospital said that they have identified pluripotent stem cells from patients to aid in the diagnosis and treatment of a variety of disorders as their goal is to advance their understanding of genetic maladies.
The process involves beginning with the acquisition of blood samples from patients and subjecting these cells to conditions that choose pluripotent stem cells.
Cells are plated and individual colonies selected and isolated individually. Selected candidates can be programmed through manipulation of culture conditions to differentiate into the liver, cardiac, or other differentiated cell types that are then characterized and evaluated for their response to a range of therapeutic agents.
The director added that this process can be, however, labor-intensive and time-consuming as it requires several months to be completed, yielding a differentiated cell line from each patient that can be toxicity tested for sensitivity to therapeutic agents under a wide variety of conditions.
Although there are available automated systems for stem cell isolation and processing, these are not cost-effective for an individualized protocol targeting helps individual patients with grievous conditions such as muscular dystrophy, cardiovascular disorders, and autoimmune dysfunction.
Their incremental improvements are constantly moving the industry forward.